The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
34844889
DOI
10.1016/j.clbc.2021.10.007
PII: S1526-8209(21)00301-3
Knihovny.cz E-resources
- Keywords
- Chemotherapy, Cytotoxic, HR positive, Metastatic breast cancer,
- MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Breast Neoplasms * pathology MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Receptor, ErbB-2 metabolism MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antineoplastic Agents * MeSH
- Receptor, ErbB-2 MeSH
Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines current HR-positive/HER2-negative MBC clinical guidelines and addresses key questions around the use of chemotherapy in the face of emerging therapeutic options. Specifically, the indications for chemotherapy in patients with HR-positive/HER2-negative MBC and the choice of optimal chemotherapy are discussed.
1st Faculty of Medicine and General Teaching Hospital Charles University Prague Czech Republic
Department of Medicine 1 Division of Oncology Medical University of Vienna Austria
Department of Oncology Kaplan Medical Center Rehovot Israel
Division of Medical Oncology Institute of Oncology Ljubljana Slovenia
ICANS Strasbourg Europe Cancerology Institute Strasbourg France
Loginov Moscow Clinical Scientific Center Moscow Russia
References provided by Crossref.org
